Insider Selling: DexCom (NASDAQ:DXCM) Director Sells $130,231.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 1,550 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $84.02, for a total value of $130,231.00. Following the completion of the transaction, the director owned 35,832 shares of the company’s stock, valued at approximately $3,010,604.64. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nicholas Augustinos also recently made the following trade(s):

• On Tuesday, September 15th, Nicholas Augustinos sold 6,539 shares of DexCom stock. The shares were sold at an average price of $84.04, for a total value of $549,537.56.

DexCom Price Performance

Shares of DXCM traded up $0.89 during midday trading on Wednesday, hitting $87.34. 3,541,995 shares of the company traded hands, compared to its average volume of 5,115,788. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The firm has a market cap of $32.96 billion, a P/E ratio of 34.52, a PEG ratio of 1.42 and a beta of 1.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The stock has a 50-day moving average of $83.25 and a 200-day moving average of $72.98.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s revenue was up 13.1% compared to the same quarter last year. During the same period last year, the business earned $0.48 earnings per share. As a group, sell-side analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Argus raised their price target on shares of DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Piper Sandler reiterated an “overweight” rating and issued a $95.00 price objective (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. UBS Group set a $96.00 price objective on DexCom and gave the company a “buy” rating in a research note on Tuesday, July 28th. Royal Bank Of Canada boosted their target price on DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $94.00 target price on shares of DexCom in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $88.71.

Hedge Funds Weigh In On DexCom

Institutional investors have recently made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB boosted its position in shares of DexCom by 15.4% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after purchasing an additional 153 shares in the last quarter. V Square Quantitative Management LLC increased its position in DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after buying an additional 172 shares in the last quarter. Essex Financial Services Inc. raised its stake in DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after buying an additional 175 shares during the last quarter. Gabelli Funds LLC raised its stake in DexCom by 0.4% in the fourth quarter. Gabelli Funds LLC now owns 50,200 shares of the medical device company’s stock valued at $3,332,000 after buying an additional 200 shares during the last quarter. Finally, One Wealth Map LLC boosted its holdings in DexCom by 5.6% in the first quarter. One Wealth Map LLC now owns 4,900 shares of the medical device company’s stock worth $301,000 after acquiring an additional 261 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.